Loading...
Tarlatamab is a bispecific T-cell engager that targets delta-like ligand 3 and CD3. In the industry-funded, phase 2 DeLLphi-301 study, researchers evaluated the activity and safety of tarlatamab in 220 patients with advanced small-cell lung cancer (SCLC) previously treated with two or more lines of therapy. In the open-label trial, patients received either 10 mg or 100 mg of tarlatamab every 2 weeks.
At a median follow-up of approximately 10 months, the objective response rate – the primary endpoint — among the 188 evaluable patients was 40% in the 10-mg group and 32% in the 100-mg group. Among 68 patients with an objective response, the duration of response was ≥6 months in 59%. The estimated overall survival rate at 9 months was 68% in the…